• In the past quarter, DaVita Inc. reported Q2 2026 revenue of US$3,554.08 million and net income of US$265.4 million, with diluted EPS from continuing operations rising to US$4.02 from US$2.58 a year earlier.
• Beyond the headline growth, DaVita paired higher earnings with improved patient mortality, stronger treatment volumes, and an accelerated rollout of advanced hemodialysis dialyzers following recent FDA approvals.
• We'll now examine how DaVita's improved mortality trends and expanding hemodialysis initiatives influence its previously outlined investment narrative.

Capitalize on the AI infrastructure supercycle with our selection of the 56 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.

DaVita Investment Narrative Recap

To own DaVita, you need to believe its core dialysis business can convert clinical gains into steadier treatment growth while managing reimbursement and cost pressures. The latest quarter supports this thesis in the near term, with higher earnings coinciding with better mortality and stronger volumes, which directly addresses the earlier concern about persistently elevated mortality. The biggest ongoing risk remains margin pressure from reimbursement and input costs, and this update does not fundamentally change that.

The most relevant recent announcement here is DaVita’s reaffirmation of its 2026 outlook alongside Q2 2026 adjusted EPS of US$4.02 and adjusted operating income of US$579 million. Management tied this confidence to improved mortality, slightly faster than expected U.S. treatment volume growth, and the planned broad deployment of expanded hemodialysis using newly approved dialyzers, which together support the near term volume catalyst while still sitting against reimbursement and cost headwinds.

Yet beneath the improving mortality data, investors should be aware of how slower reimbursement growth and rising costs could still…

DaVita's narrative projects $15.7 billion revenue and $1.1 billion earnings by 2029. This requires 4.2% yearly revenue growth and an earnings increase of about $0.3 billion from $756.4 million today.

Uncover how DaVita's forecasts yield a $208.57 fair value, a 15% upside to its current price.

Exploring Other Perspectives

While consensus focuses on improving mortality and volumes, the most pessimistic analysts were assuming only about US$14.9 billion of revenue and US$1.1 billion of earnings by 2029, so this quarter’s stronger results could eventually push their more cautious view on delayed clinical benefits and margin pressure to evolve in a very different direction.

Explore 3 other fair value estimates on DaVita - why the stock might be worth just $208.57!

Decide For Yourself

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your DaVita research is our analysis highlighting 3 key rewards and 2 important warning signs that could impact your investment decision.
• Our free DaVita research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate DaVita's overall financial health at a glance.

Curious About Other Options?

Our daily scans reveal stocks with breakout potential. Don't miss this chance:

• Outshine the giants: these 16 early-stage AI stocks could fund your retirement.
• The future of work is here. Discover the 36 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.
• Invest in the nuclear renaissance through our list of 89 elite nuclear energy infrastructure plays powering the global AI revolution.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.